Citations

Showing 10 of 108152 citations.

P035 Clostridium difficile infection in ulcerative colitis: Data from the tofacitinib clinical program and an insurance claims database
Edward, Loftus, Baumgart, Daniel, Marco, DiBonaventura, Jeffrey, Curtis, Gary, Chan, Eric, Maller, Quirk, Daniel, Fan, Haiyun, Koram, Nana , Salese, Leonardo , Su, Chinyu , Armuzzi, Alessandro , Marco, DiBonaventura, Gary, Chan

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S10-S10

10.14309/01.ajg.0000578212.86577.86 Get It

BACKGROUND: Patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), have a higher risk of Clostridium difficile infection (CDI) than the general population (1). The incidence of CDI is increasing among patients with IBD, and certain UC treatments may be associated with greater risk (1). We report CDI events in the tofacitinib UC clinical program, and the incidence of CDI among patients receiving other treatments for UC. METHODS: For the tofacitinib UC program, rates of CDI (patients with an adverse event [AE] of CDI, Clostridium difficile colitis, or Clostridium test-positive, plus concomitant oral metronidazole or vancomycin, counted once per cohort) are reported for Induction Cohort (patients from an 8-week Phase [P]2 and two 8-week P3 induction studies; placebo or tofacitinib 10 mg twice daily [BID; NCT00787202; NCT01465763; NCT01458951]); Maintenance Cohort (patients from a 52-week maintenance study; placebo or tofacitinib 5 or 10 mg BID [NCT01458574]); and Overall Cohort (all tofacitinib-treated patients in P2/3 induction and maintenance studies and an ongoing, open-label, long-term extension study [as of December 2016; NCT01470612]). Positive Clostridium difficile test at screening was an exclusion criterion for program entry. Overall Cohort incidence rate (IR) was calculated as number of unique patients with events per 100 patient-years (PY). For contextualization, CDI rates among patients receiving other UC medications were obtained from a retrospective cohort study utilizing data from the Truven MarketScan ® Database, an administrative healthcare claims database in the US. Patients with moderately to severely active UC, with either an inpatient or outpatient diagnosis code of CDI, plus a prescription for oral therapy (including metronidazole, vancomycin, and fidaxomicin) within 14 days of CDI diagnosis (observation period: October 1, 2010–September 30, 2015), were included. Truven cohort IRs were calculated as number of patients with events per 100 PY. RESULTS: In the tofacitinib Induction Cohort, CDI occurred in 3 patients (placebo, 1/282 [0.4%]; tofacitinib 10 mg BID, 2/938 [0.2%]). In the Maintenance Cohort, CDI occurred in 3 patients (placebo, 3/198 [1.5%]; tofacitinib 5 or 10 mg BID, 0/394 [0.0%]). In the Overall Cohort of all tofacitinib-treated patients (1,664 PY of follow-up), CDI occurred in 8/1,157 patients (0.7%), with an IR (95% confidence interval [CI]) of 0.48 (0.21, 0.95). Two cases were reported as serious AEs. All were mild (n = 4) or moderate (n = 4) in severity; 6 continued with study treatment, one temporarily discontinued, one permanently discontinued. All CDI cases resolved with treatment. In the Truven Cohort, 160 CDI events occurred during 4,918 PY of follow-up, with an overall CDI IR (95% CI) of 3.25 (2.77, 3.80); of which 116 were CDI-associated hospitalizations (4,936 PY of follow-up). Among patients receiving azathioprine, 6-mercaptopurine, or tumor necrosis factor inhibitors, CDI IRs were 3.23 (2.18, 4.62), 2.31 (1.26, 3.87), and 3.58 (2.95, 4.29), respectively. CONCLUSION(S): In the tofacitinib UC program, CDI rates among patients receiving tofacitinib were similar to or lower than those observed with placebo. The IR among patients receiving tofacitinib was numerically lower than those observed for immunomodulators and tumor necrosis factor inhibitors in the Truven Cohort.
P034 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical program
Gary, Lichtenstein, Bressler, Brian , Gary, Chan, Su, Chinyu , Gary, Friedman, Lawendy, Nervin, Ronald, Pedersen, Salese, Leonardo , Edward, Loftus, Gary, Chan

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S9-S9

10.14309/01.ajg.0000578208.09449.08 Get It

BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Safety and efficacy of tofacitinib were demonstrated in Phase (P) 2/3 induction studies (NCT00787202; NCT01465763; NCT01458951), a 52-week, P3 maintenance study (NCT01458574), and are being further investigated in an ongoing, open-label, long-term extension (OLE) study (NCT01470612). This analysis assessed age as a risk factor for adverse events (AEs) in the tofacitinib UC clinical program. METHODS: Analyses of AEs were performed for 2 cohorts: the Maintenance Cohort (patients who received placebo or tofacitinib 5 or 10 mg twice daily in the maintenance study) and the Overall Cohort (all tofacitinib-treated patients in the P2/P3/OLE studies [as of December 2016]), stratified by age (≥65 years vs <65 years). AEs of special interest included serious infections (SIs), opportunistic infections (OIs), herpes zoster (HZ), malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC, major adverse cardiovascular events (MACE), and gastrointestinal perforations. Risk factors (based on baseline characteristics) for SIs, OIs, HZ, and NMSC in the Overall Cohort were evaluated using multivariate Cox proportional regression models. RESULTS: AEs occurred in 75.3% (placebo) and 75.9% (tofacitinib) of patients in the Maintenance Cohort, and 82.1% in the Overall Cohort (in which 83.9% received predominantly tofacitinib 10 mg twice daily). Most patients (Maintenance Cohort: 180/198 [90.9%] and 364/394 [92.4%] receiving placebo and tofacitinib, respectively; Overall Cohort: 1,080/1,157 [93.3%]) were aged <65 years. In both the placebo and tofacitinib groups of the Maintenance Cohort, rates of AEs, serious AEs, severe AEs, and discontinuations due to AEs were numerically higher in patients aged ≥65 years (placebo: 83.3%, 11.1%, 11.1%, and 22.2%; tofacitinib: 80.0%, 16.7%, 10.0%, and 16.7%) vs <65 years (placebo: 74.4%, 6.1%, 9.4%, and 18.3%; tofacitinib: 75.5%, 4.4%, 7.1%, and 8.8%). AEs of special interest were generally infrequent in both the placebo and tofacitinib groups of the Maintenance Cohort. In the Overall Cohort, AE, serious AE, and severe AE rates were numerically higher in patients aged ≥65 years (88.3%, 19.5%, and 15.6%) vs <65 years (81.7%, 14.3%, and 12.2%). OI, HZ, malignancies (excluding NMSC), NMSC, and MACE rates were numerically higher in patients aged ≥65 years (3.9%, 14.3%, 2.6%, 5.3%, and 2.6%) vs <65 years (1.7%, 5.0%, 0.6%, 0.7%, and 0.2%); SI and gastrointestinal perforation rates were similar between age groups (≥65 years: 2.6% and 0.0%; <65 years: 2.9% and 0.4%). In multivariate modeling in the Overall Cohort, increasing age (every 10 years) was associated with increased risk of OIs (hazard ratio [95% confidence interval] 1.54 [1.15, 2.08]) and HZ (1.58 [1.34, 1.87]), but not SIs or NMSC (univariate modeling: 1.0 [0.78, 1.27] and 2.31 [1.46, 3.66]). CONCLUSION(S): In the tofacitinib UC program, AE rates were higher among patients aged ≥65 years vs those aged <65 years, regardless of whether they received tofacitinib or placebo. In multivariate analyses, older age was associated with increased OI and HZ risk. Although this is consistent with the general population, due to the small number of patients aged ≥65 years (<10% of the total), these findings should be interpreted with caution.
P008  Improving efficiency with a nurse driven immunomodulator lab monitoring tracking tool
Shari, Frueh, Ashley, Grinhaug, Kati, Cavanaugh, Patricia, Winzenburg, Desiree, Tynsky

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S3-S3

10.14309/01.ajg.0000578104.80739.a1 Get It

BACKGROUND: Immunomodulator medications are commonly used in the care of patients with inflammatory bowel disease (IBD). American College of Gastroenterology's and American Gastroenterology Association's IBD practice guidelines recommend routine lab monitoring during initiation of and ongoing medication therapy to avoid the risk of acute or delayed bone marrow suppression and/or liver toxicity. Within the IBD clinic at a large academic medical center, registered nurses (RNs) routinely monitor lab results of patients enrolled in a lab monitoring program. Lab results were previously monitored using an institutionally created guideline and messaging system within an electronic health record (EHR) that was being discontinued. The messaging tool was suboptimal and limited the RNs ability to view the total volume of patients in the lab monitoring program. Additionally, there was no efficient way to view lab due dates, differentiate internal vs external lab collection expectations, track patient's compliance with lab monitoring requirements, nor efficient tracking of patients requiring more frequent monitoring due to abnormal test results. Subsequently, these inefficiencies made it difficult for nurse leaders to assess the nursing workload associated with the coordination of care for these patients. AIM: The primary endpoint was to develop electronic tools specifically designed for immunomodulator lab monitoring, which would assist with RN efficiency in tracking a large volume of patients enrolled in the required lab monitoring. METHODS: Input was obtained by benchmarking with similar nursing workflows involving patients requiring close monitoring; and brainstorming with the RN team regarding essential elements to place within the report. Informatics colleagues assisted in the design and development of the electronic tools. RESULTS: Development of an immunomodulator-specific electronic tracking tool that is integrated into the new EHR. The closer tracking of patient adherence improves quality and safety for patients taking these medications. The new tool allows convenient access to the following information (was not previously available): Volume of patients enrolled, Due dates for required lab tests (delinquent or next expected result), Quick links to view lab results, At-a-glance way to see which patients are high priority for next lab results, Stratifying options to track patient enrollment by provider, specific drug prescribed, medication start date, internal/external lab location, pending enrollments and more. Additional outcomes included: Written standardized RN workflows, Defined RN training program and written reference guides, Adapting the standardized IBD tool for use within the hepatitis C and Hepatobiliary practices, Quantifiable data available for future analysis related to nursing workload. CONCLUSION: Development of a comprehensive EHR-integrated lab monitoring tool allows an IBD practice to more efficiently track patient adherence, which in turn improves quality and safety for patients taking these medications. Additionally, the report tool is an initial step toward better quantification of the nursing workload associated with the ongoing care coordination required with this patient population.
A Prospective Multicenter Study Evaluating Endoscopy Competence Among Gastroenterology Trainees in the Era of the Next Accreditation System
Han, Samuel , Obuch, Joshua , Duloy, Anna , Keswani, Rajesh N. , Simon, Violette C., Ezekwe, Eze, Menard‐Katcher, Paul , Patel, Swati , Aagard, Eva, Brimhall, Bryan , Ahmad, Asyia, Broy, Charles, Carlin, Linda, Connolly, Seán , Cooley, David , Cowley, Kevin, Palma, Jack A. Di, Early, Dayna S., Ellert, Swan , Gaumnitz, Eric A., Ghassemi, Kevin A., Lebovics, Edward, Lee, Robert , Lunsford, Tisha , Massaad, Julia , Mittal, Mohit , Morigeau, Kirsten, Pietrak, Stanley, Piper, Michael , Shah, Anand S. , Shapiro, Alan, Sonnier, William, Sorrell, Cari, Vignesh, Shivakumar , Woolard, Shani, Wani, Sachin , Hall, Matt , Alghamdi, Saad Ali , Brown, Michael D. , Chugh, Priyanka , Connolly, Sean E., Cooley, D. Matthew

Mayo Clinic

Academic Medicine | July 21, 2019 | Volume: 95 | Issue: 2 | Pages: 283-292

10.1097/acm.0000000000002885 | PMID 31335810 Get It

Purpose The Next Accreditation System requires training programs to demonstrate competence among trainees. Within gastroenterology (GI), there are limited data describing learning curves and structured assessment of competence in esophagogastroduodenoscopy (EGD) and colonoscopy. In this study, the authors aimed to demonstrate the feasibility of a centralized feedback system to assess endoscopy learning curves among GI trainees in EGD and colonoscopy. Method During academic year 2016–2017, the authors performed a prospective multicenter cohort study, inviting participants from multiple GI training programs. Trainee technical and cognitive skills were assessed using a validated competence assessment tool. An integrated, comprehensive data collection and reporting system was created to apply cumulative sum analysis to generate learning curves that were shared with program directors and trainees on a quarterly basis. Results Out of 183 fellowships invited, 129 trainees from 12 GI fellowships participated, with an overall trainee participation rate of 72.1% (93/129); the highest participation level was among first-year trainees (90.9%; 80/88), and the lowest was among third-year trainees (51.2%; 27/53). In all, 1,385 EGDs and 1,293 colonoscopies were assessed. On aggregate learning curve analysis, third-year trainees achieved competence in overall technical and cognitive skills, while first- and second-year trainees demonstrated the need for ongoing supervision and training in the majority of technical and cognitive skills. Conclusions This study demonstrated the feasibility of using a centralized feedback system for the evaluation and documentation of trainee performance in EGD and colonoscopy. Furthermore, third-year trainees achieved competence in both endoscopic procedures, validating the effectiveness of current training programs.
Teaching Systems Improvement to Early Medical Students: Strategies and Lessons Learned
Harbell, Monica W. , Li, Descartes , Pierluissi, Edgar, Harbell, Monica W , Boscardin, Christy , Hauer, Karen E.

Mayo Clinic

Academic Medicine | July 21, 2019 | Volume: 95 | Issue: 1 | Pages: 136-144

10.1097/acm.0000000000002886 | PMID 31335811 Get It

Purpose Despite increasing emphasis in medical school education on quality and systems improvement, many medical schools lack sufficient faculty with expertise to teach systems improvement. Using the pedagogical content knowledge framework, this study explores how faculty engage students in systems improvement work and faculty perceptions of the outcomes for the health system and students. Method In May–June 2017, the authors interviewed 12 of 13 invited faculty with experience in teaching and engaging first-year medical students in systems improvement work, the course of students’ systems improvement work over time, the impact of students’ projects on health systems, and students’ learning and attitudes about systems improvement. The authors conducted qualitative analysis iteratively with data collection to sufficiency. Results Six emergent themes characterized faculty’s approach to guiding students in systems improvement work: faculty–student relationship, faculty role, student role, faculty–student shared responsibility for projects, faculty and student content knowledge, and project outcomes. The faculty–student relationship was foundational for successful systems improvement work. Faculty roles included project selection, project management, and health systems interactions. Students engaged in systems improvement as their faculty leveraged their knowledge and skills and created meaningful student roles. Faculty and students shared responsibility and colearned systems improvement content knowledge. Faculty defined successful outcomes as students’ learning about the systems improvement process and interprofessional collaboration. Conclusions Findings highlight the critical importance of pedagogical content knowledge to engage early learners in systems improvement work, understand their learning interests and needs, and manage their projects longitudinally.
Profiling Multiscale Frequency State of Normal Phonocardiogram: Feasibility Study
Sundaram, Divaakar Siva Baala, Anjani, Muthyala, Balasubramani, Rogith, Shivaram, Suganti, Karki, Susan, Arunachalam, S P , Karki, Susan, Arunachalam, Shivaram P.

Mayo Clinic

2019 Design of Medical Devices Conference | July 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2019-3301 Get It

Phonocardiogram (PCG) signals contain very important information regarding the heart condition. Recently, several automatic detection algorithms have been explored to profile the characteristics of heart sounds to aid in disease diagnosis. However, many of these methods has been demonstrated only on clean signals with limited test data and variety of PCG signals that can accurately provide information of diagnostic importance with higher sensitivity and specificity. In this work, we propose to characterize the multiscale frequency state of the normal PCG signals that can aid in accurate profiling of PCG to discriminate from pathological conditions.
Femtosecond Laser Ablation of Implantable Materials
McEligot, Patrick, Hara, Seth A. , Uthamaraj, Susheil

Mayo Clinic

2019 Design of Medical Devices Conference | July 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2019-3263 Get It

Femtosecond laser ablation is a powerful tool for the fabrication of medical devices, especially with materials commonly used in implantable micro devices as these materials are often incompatible with traditional machining techniques. Laser machining quality is highly dependent not only on the laser parameters, but also on the material that is being machined and so the process must be characterized for each material of interest. In this work, process characterization is presented for two materials commonly used in implantable micro devices — polyimide and silicon. The ablation threshold and etch rate were determined for femtosecond laser machining with a UV wavelength.
Standardizing Febrile Neutropenia Management: Antimicrobial Stewardship in the Hematologic Malignancy Population
Marcelin, Jasmine R , Saleh, Omar Abu , Barwise, Amelia , Odean, Patricia M., Rivera, Christina G. , Tande, Aaron J. , Wilson, John , Osmon, Douglas R. , Tosh, Pritish K. , O'Horo, John C, Abu Saleh, Omar M, Barwise, Amelia K, Tande, Aaron , Marcelin, Jasmine , Barwise, Amelia K , Rivera, Christina G , O’Horo, John C.

Mayo Clinic

Journal of Oncology Practice | July 19, 2019 | Volume: 15 | Issue: 9 | Pages: e843-e848

10.1200/jop.18.00775 | PMID 31322989 Get It

Patients with febrile neutropenia (FN) often are subject to antibiotic and diagnostic test overuse. We sought to improve appropriate use of antimicrobials and diagnostic tests for patients with FN. We used a blended quality approach with Lean Six Sigma tools and iterative improvement of a clinical decision aid to guide providers through empirical antimicrobial selection and diagnostic evaluation of patients with FN during a yearlong period. We evaluated the incidence of nonadherence to best practice before, during, and after rollout of a clinical decision aid in conjunction with an educational initiative. At baseline, 71% of patients with FN had at least one critical deviation from best practice. During the project, the percentage decreased to 27.3%; 4 months after the project was completed, the percentage was 33.3% ( P = .04). A clinical decision aid can improve adherence to best practices for the empirical management of FN.
High Rate of Recurrent Meniscal Tear and Lateral Compartment Osteoarthritis in Patients Treated for Symptomatic Lateral Discoid Meniscus: A Population-Based Study
Sabbag, Orlando D., Sanders, Thomas L. , Dahm, Diane L., Levy, Bruce A. , Krych, Aaron J. , Krych, Aaron J , Hevesi, Mario , Camp, Christopher L. , Stuart, Michael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 19, 2019 | Volume: 7 | Issue: 7 | Pages: No page available

10.1177/2325967119856284 | PMID 31367646 Get It

Background: Little is known about the natural history of a surgically treated symptomatic lateral discoid meniscus. The goals of this study were to describe the rate and factors associated with recurrent lateral meniscal tears and progression to symptomatic lateral compartment osteoarthritis (OA) in patients surgically treated for a symptomatic lateral discoid meniscus. Hypothesis: Patients with surgically treated lateral discoid meniscus have a high incidence of meniscal retear and progression to lateral compartment OA. Study Design: Case series; Level of evidence, 4. Methods: A large geographic database was reviewed to identify and confirm patients presenting with symptomatic lateral discoid meniscus between 1998 and 2015. Charts were reviewed to document treatment and outcomes at a minimum clinical follow-up of 2 years. Results: A total of 59 patients (27 females, 32 males) with a mean age of 25.7 years (range, 4.0-66.0 years) underwent surgical management of a discoid lateral meniscus and were evaluated for a mean of 5.6 years (range, 2.0-23.7 years). Of these, 48 (82%) patients underwent partial lateral meniscectomy, with 24 patients undergoing concurrent saucerization. Eleven (18%) underwent meniscal repair. Tear-free survival following surgery was 41% at 8 years. Progression to symptomatic lateral compartment OA was 50% at 8 years. Young age (hazard ratio, 0.96; 95% CI, 0.93-0.99; P = .01) and open growth plates (hazard ratio, 3.19; 95% CI, 1.15-8.88; P = .03) were associated with increased incidence of postoperative retear. Older age at diagnosis and body mass index ≥30 kg/m 2 were associated with increased risk of progression to lateral compartment OA on final radiographs. Conclusion: Patients with a surgically treated lateral discoid meniscal tear had a high rate of recurrent meniscal tear (59% at 8 years). Approximately 50% of surgically treated patients developed symptomatic lateral compartment OA at 8 years from diagnosis.